Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CHMP Adopts Positive Opinion On ADASUVE - Quick Facts

RELATED NEWS
Trade ALXA now with 

Alexza Pharmaceuticals, Inc. (ALXA: Quote) and Grupo Ferrer Internacional, S.A., announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending that ADASUVE be granted European Union centralized marketing authorization.

The CHMP recommends ADASUVE be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.

The CHMP positive opinion will now be forwarded to the European Commission. The company expects a decision from the European Commission in the first quarter of 2013.

Alexza filed the ADASUVE Marketing Authorization Application with the European Medicines Agency in October 2011.

Click here to receive FREE breaking news email alerts for Alexza Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The U.K. economy grew at a slower pace in the third quarter in the face of rising uncertainty stemming from global economic conditions, preliminary estimates from the Office for National Statistics Office showed Friday. Gross domestic product climbed 0.7 percent from the second quarter, when it grew 0.9 percent. German consumer climate is set to improve slightly in November, ending the downward trend, as income expectations among households strengthened on the back of the strong labor market situation, survey data revealed Friday.The forward-looking consumer confidence index rose slightly to 8.5 in November from 8.4 in October. Software giant Microsoft Corp. said Thursday after the markets closed that its first quarter profit fell 13% from last year, hurt mainly by integration and restructuring costs even as revenue surged 25% thanks to strong sales of its gadgets and cloud-based products. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.